Chondroplus: The Ideal Solution When Life Won't Wait

  • A single physician visit.

  • One powerful injection administration.

  • Designed to increase residence time within the knee joint for prolonged comfort support.

CHONDROPLUS is a single-injection viscosupplementation treatment composed of hyaluronic acid and collagen tripeptide, developed for the management of knee osteoarthritis symptoms.

It offers a longer-lasting efficacy profile compared to standard hyaluronic acid injections and steroid treatments. Chosen by over a million patients worldwide, Chondroplus delivers clinical performance comparable to 3 or 5-injection therapies for pain management, while significantly supporting the quality of life for knee osteoarthritis patients during the early post-injection period.

 

What is Chondroplus?

CHONDROPLUS is a natural, non-opioid clinical approach formulated for the management of knee discomfort caused by osteoarthritis. It is a single-session intra-articular injection combining hyaluronic acid (HA) and collagen tripeptide (CTP) to offer sustained relief. Hyaluronic acid naturally acts as a lubricant and shock absorber in the knee joint, and CHONDROPLUS contains this essential biological substance.

What sets CHONDROPLUS apart is its concentrated, stabilized form of HA combined with synthetic CTP, engineered to resist enzymatic breakdown. This design allows the product to remain within the joint space for an extended duration, enhancing its prolonged effect potential.

Introduced globally in 2014, CHONDROPLUS has been extensively evaluated in clinical trials exceeding those of any other single-injection hyaluronic acid therapy. It is a proven and reliable option for repeat treatments, demonstrating a more durable comfort period compared to steroid and standard HA injections. The hyaluronic acid in CHONDROPLUS is derived from a non-animal source, minimizing the potential risk of hypersensitivity.

 

Mechanism of Action

Chondroplus has been developed and manufactured based on scientific data.

The primary principle of the product is to stimulate the production of endogenous hyaluronic acid (HA) by type B synovial cells.

These cells are activated via HA receptors on their surface. Once stimulated, they release endogenous HA into the synovial space.

Endogenously produced HA initially features a very high molecular weight (~40 million Daltons).

Over time, this HA undergoes physiological degradation (physical and chemical breakdown), resulting in molecules with a molecular weight of 2 to 4 million Daltons.

These medium-sized HA molecules also bind to synovial cell receptors, re-stimulating type B synoviocytes and ensuring a continuous cycle of HA production.

In inflammatory conditions such as osteoarthritis, the natural balance of the joint environment is disrupted. This occurs due to the excessive degradation of endogenous hyaluronan (HA) and insufficient stimulation of type B synoviocytes. To balance this cycle, exogenous hyaluronan supplementation is clinically significant.

 

Safety Profile

CHONDROPLUS has been shown to be safe and effective, supported by a history of extensive clinical evaluations exceeding those of any other single-injection knee hyaluronic acid therapy.

In pivotal CHONDROPLUS clinical trials:

  • No serious adverse events were deemed related to the treatment with CHONDROPLUS.

  • The most frequently reported transient events were joint pain (8.6%), injection site pain (2.3%), and joint swelling (1.7%).

  • CHONDROPLUS is safe for repeated courses of therapy, and repeat administration does not increase the incidence of adverse events.

Choose CHONDROPLUS for extended-lasting results:

  • It features a total joint residence time of approximately 150 days, based on a half-life of 30 days.

  • The reported half-life of 30 days in the knee joint for a single injection regimen represents one of the longest retention durations among HA formulations.

FATS Global, operating as an affiliate of Germany-based TBF Global Med. GmbH, holds exclusive worldwide commercialization and distribution rights for the France-origin CHONDROPLUS® intra-articular product portfolios.